Growth hormone secretagogue: difference between revisions
Diff·revision 7 → 8·12:07, 2 Feb 2025
Difference between revision 7 and revision 8 of Growth hormone secretagogue. 6 lines changed; the page grew by 629 bytes.
| Revision 7 — 02:33, 14 Jan 2025 SemaxSevi (talk) the lead said "widely used"; replaced with what the sources actually support 2,721 bytes ±0 | Revision 8 — 12:07, 2 Feb 2025 UnderfillUna (talk) alphabetise the see-also list 3,350 bytes +629 | ||
|---|---|---|---|
| 1 | {{Infobox concept | 1 | {{Infobox concept |
| 2 | | name = Growth hormone secretagogue | 2 | | name = Growth hormone secretagogue |
| + | 3 | | subtitle = Research peptides | |
| 3 | | Two receptor families = GHRH receptor; ghrelin receptor (GHS-R1a) | 4 | | Two receptor families = GHRH receptor; ghrelin receptor (GHS-R1a) |
| 4 | | GHRH analogues = [[Sermorelin]], [[CJC-1295]], [[Tesamorelin]] | 5 | | GHRH analogues = [[Sermorelin]], [[CJC-1295]], [[Tesamorelin]] |
| ⋮ | ⋮ | ||
| 19 | 20 | ||
| 20 | Feedback remains intact in both cases: rising growth hormone and insulin-like growth factor 1 suppress further release. This is the mechanistic reason a secretagogue cannot produce the exposures achievable with exogenous growth hormone.{{r|molitch2011}} | 21 | Feedback remains intact in both cases: rising growth hormone and insulin-like growth factor 1 suppress further release. This is the mechanistic reason a secretagogue cannot produce the exposures achievable with exogenous growth hormone.{{r|molitch2011}} |
| + | 22 | ||
| + | 23 | == Evidence and status == | |
| + | 24 | [[Tesamorelin|Tesamorelin]] is approved for a specific indication — reduction of excess visceral adipose tissue in a defined population — and has trial evidence supporting it. Most other compounds in this group are not approved for any indication and are distributed as research chemicals.{{r|molitch2011}} | |
| + | 25 | ||
| + | 26 | The evidence base for the unapproved compounds is thin: small studies, short durations, surrogate endpoints such as growth hormone or IGF-1 concentration rather than clinical outcomes, and in several cases no controlled human data at all.{{r|sigalos2018}} | |
| 21 | 27 | ||
| 22 | == References == | 28 | == References == |